Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 461

1.

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, Cofrancesco J Jr, Gallant JE, Quinn TC, Jackson B, Flexner C, Carson K, Ray S, Persaud D, Siliciano RF.

JAMA. 2005 Feb 16;293(7):817-29.

PMID:
15713771
[PubMed - indexed for MEDLINE]
2.

HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.

Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D'Aquila RT, Quinn TC, Siliciano JD, Siliciano RF, Persaud D.

JAMA. 2001 Jul 11;286(2):196-207.

PMID:
11448283
[PubMed - indexed for MEDLINE]
3.

Prevalence and predictive value of intermittent viremia with combination hiv therapy.

Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Günthard HF, Richman DD, Wong JK.

JAMA. 2001 Jul 11;286(2):171-9.

PMID:
11448280
[PubMed - indexed for MEDLINE]
4.

Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.

Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG.

Clin Infect Dis. 2005 Nov 1;41(9):1326-32. Epub 2005 Sep 29.

PMID:
16206110
[PubMed - indexed for MEDLINE]
Free Article
5.

HIV-1 viral load blips are of limited clinical significance.

Lee PK, Kieffer TL, Siliciano RF, Nettles RE.

J Antimicrob Chemother. 2006 May;57(5):803-5. Epub 2006 Mar 13.

PMID:
16533823
[PubMed - indexed for MEDLINE]
Free Article
6.

Molecular biological assessment methods and understanding the course of the HIV infection.

Katzenstein TL.

APMIS Suppl. 2003;(114):1-37. Review.

PMID:
14626050
[PubMed - indexed for MEDLINE]
7.

Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy.

Macias J, Palomares JC, Mira JA, Torres MJ, García-García JA, Rodríquez JM, Vergera S, Pineda JA.

J Infect. 2005 Oct;51(3):195-200. Epub 2005 Jan 12.

PMID:
16230215
[PubMed - indexed for MEDLINE]
8.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA.

J Med Virol. 2005 Sep;77(1):23-8.

PMID:
16032728
[PubMed - indexed for MEDLINE]
9.

Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection.

Di Mascio M, Markowitz M, Louie M, Hurley A, Hogan C, Simon V, Follmann D, Ho DD, Perelson AS.

J Virol. 2004 Oct;78(19):10566-73.

PMID:
15367623
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance.

Cohen Stuart JW, Wensing AM, Kovacs C, Righart M, de Jong D, Kaye S, Schuurman R, Visser CJ, Boucher CA.

J Acquir Immune Defic Syndr. 2001 Oct 1;28(2):105-13.

PMID:
11588503
[PubMed - indexed for MEDLINE]
11.

Update on HIV-1 viral load blips.

Nettles RE, Kieffer TL.

Curr Opin HIV AIDS. 2006 Mar;1(2):157-61. doi: 10.1097/01.COH.0000203834.24221.13.

PMID:
19372801
[PubMed]
12.

Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy.

Nettles RE, Kieffer TL, Simmons RP, Cofrancesco J Jr, Moore RD, Gallant JE, Persaud D, Siliciano RF.

Clin Infect Dis. 2004 Oct 1;39(7):1030-7. Epub 2004 Sep 1.

PMID:
15472857
[PubMed - indexed for MEDLINE]
Free Article
13.

Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, Peytavin G, Tubiana R, Pialoux G, Katlama C.

Clin Infect Dis. 2010 Mar 1;50(5):773-8. doi: 10.1086/650538.

PMID:
20100092
[PubMed - indexed for MEDLINE]
Free Article
14.

Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy.

Di Mascio M, Ribeiro RM, Markowitz M, Ho DD, Perelson AS.

Math Biosci. 2004 Mar-Apr;188:47-62.

PMID:
14766093
[PubMed - indexed for MEDLINE]
15.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
[PubMed - indexed for MEDLINE]
16.

Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.

Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ.

J Infect Dis. 2007 Dec 15;196(12):1773-8. doi: 10.1086/523704.

PMID:
18190257
[PubMed - indexed for MEDLINE]
Free Article
17.

Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.

de Mendoza C, Soriano V, Pérez-Olmeda M, Rodés B, Casas E, González-Lahoz J.

J Hum Virol. 1999 Nov-Dec;2(6):344-9.

PMID:
10774551
[PubMed - indexed for MEDLINE]
18.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV.

MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55.

PMID:
12027060
[PubMed - indexed for MEDLINE]
Free Article
19.

Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.

Pariente N, Pernas M, de la Rosa R, Gómez-Mariano G, Fernández G, Rubio A, López M, Benito JM, López-Galíndez C, Leal M, Domingo E, Martinez MA, Mas A.

J Med Virol. 2004 Jul;73(3):350-61.

PMID:
15170628
[PubMed - indexed for MEDLINE]
20.

Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.

Mohey R, Jørgensen LB, Møller BK, Black FT, Kjems J, Obel N.

J Clin Virol. 2005 Dec;34(4):257-67. Epub 2005 Apr 18.

PMID:
16286049
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk